HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company, has successfully regained compliance with all Nasdaq Capital Market listing requirements. The company received confirmation from Nasdaq on June 24, 2025 that it met the minimum stockholders' equity requirement (Rule 5550(b)(1)).
Previously, on May 13, 2025, HCWB had already regained compliance with other crucial requirements including bid price (Rule 5550(a)(2)), public float (Rule 5550(a)(4)), and market value of publicly held shares (Rule 5550(a)(5)). The company, which focuses on developing innovative immunotherapies targeting chronic inflammation, is now fully compliant for continued listing on the Nasdaq Capital Market.
HCW Biologics (NASDAQ: HCWB), una società biofarmaceutica in fase clinica, ha riconquistato con successo la conformità a tutti i requisiti di quotazione del Nasdaq Capital Market. La società ha ricevuto conferma da Nasdaq il 24 giugno 2025 di aver soddisfatto il requisito minimo di patrimonio netto degli azionisti (Regola 5550(b)(1)).
In precedenza, il 13 maggio 2025, HCWB aveva già recuperato la conformità ad altri requisiti fondamentali, tra cui il prezzo minimo delle azioni (Regola 5550(a)(2)), il flottante pubblico (Regola 5550(a)(4)) e il valore di mercato delle azioni detenute pubblicamente (Regola 5550(a)(5)). La società, che si concentra sullo sviluppo di immunoterapie innovative mirate all'infiammazione cronica, è ora pienamente conforme per la continuazione della quotazione sul Nasdaq Capital Market.
HCW Biologics (NASDAQ: HCWB), una empresa biofarmacéutica en etapa clínica, ha recuperado con éxito el cumplimiento de todos los requisitos de cotización del Nasdaq Capital Market. La compañía recibió la confirmación de Nasdaq el 24 de junio de 2025 de que cumplió con el requisito mínimo de patrimonio neto de los accionistas (Regla 5550(b)(1)).
Anteriormente, el 13 de mayo de 2025, HCWB ya había recuperado el cumplimiento de otros requisitos clave, incluyendo el precio mínimo de la acción (Regla 5550(a)(2)), el flotante público (Regla 5550(a)(4)) y el valor de mercado de las acciones en circulación (Regla 5550(a)(5)). La compañía, que se enfoca en desarrollar inmunoterapias innovadoras dirigidas a la inflamación crónica, ahora está completamente en cumplimiento para continuar su cotización en el Nasdaq Capital Market.
HCW Biologics (NASDAQ: HCWB)는 임상 단계의 생명공학 제약 회사로서, 나스닥 캐피탈 마켓 상장 요건을 모두 충족하여 성공적으로 규정을 준수하게 되었습니다. 회사는 2025년 6월 24일 나스닥으로부터 최소 주주 자본 요건(규칙 5550(b)(1))을 충족했다는 확인을 받았습니다.
이전에 2025년 5월 13일에는 HCWB가 입찰 가격(규칙 5550(a)(2)), 공공 유통 주식 수(규칙 5550(a)(4)), 그리고 공공 보유 주식의 시장 가치(규칙 5550(a)(5)) 등 다른 중요한 요건들도 이미 충족한 바 있습니다. 만성 염증을 표적으로 하는 혁신적인 면역 치료제 개발에 주력하는 이 회사는 이제 나스닥 캐피탈 마켓에서 계속 상장될 수 있는 완전한 규정 준수 상태입니다.
HCW Biologics (NASDAQ : HCWB), une société biopharmaceutique en phase clinique, a réussi à se conformer à toutes les exigences de cotation du Nasdaq Capital Market. La société a reçu la confirmation de Nasdaq le 24 juin 2025 qu'elle remplissait le critère minimum de capitaux propres des actionnaires (Règle 5550(b)(1)).
Auparavant, le 13 mai 2025, HCWB avait déjà retrouvé la conformité avec d'autres exigences clés, notamment le prix de l'offre (Règle 5550(a)(2)), la flottation publique (Règle 5550(a)(4)) et la valeur marchande des actions détenues publiquement (Règle 5550(a)(5)). La société, qui se concentre sur le développement d'immunothérapies innovantes ciblant l'inflammation chronique, est désormais pleinement conforme pour poursuivre sa cotation sur le Nasdaq Capital Market.
HCW Biologics (NASDAQ: HCWB), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat erfolgreich die Einhaltung aller Anforderungen für die Notierung am Nasdaq Capital Market wiedererlangt. Das Unternehmen erhielt am 24. Juni 2025 von Nasdaq die Bestätigung, dass es die Mindestanforderung an das Eigenkapital der Aktionäre (Regel 5550(b)(1)) erfüllt hat.
Bereits am 13. Mai 2025 hatte HCWB die Einhaltung weiterer wichtiger Anforderungen wiedererlangt, darunter den Mindestkurs (Regel 5550(a)(2)), den Streubesitz (Regel 5550(a)(4)) und den Marktwert der öffentlich gehaltenen Aktien (Regel 5550(a)(5)). Das Unternehmen, das sich auf die Entwicklung innovativer Immuntherapien zur Behandlung chronischer Entzündungen spezialisiert hat, erfüllt nun alle Voraussetzungen für die Fortsetzung der Notierung am Nasdaq Capital Market.
- Successfully regained compliance with all Nasdaq Capital Market listing requirements
- Met minimum stockholders' equity requirement
- Achieved compliance with bid price, public float, and market value requirements
- Maintained listing on Nasdaq Capital Market
- Previous non-compliance with multiple Nasdaq listing requirements indicates past financial challenges
Company in full compliance for continued listing
MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”).
On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied the requirements of the Equity Rule. On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). Therefore, the Company now meets all Nasdaq Capital Market listing requirements for continued listing, and these matters are closed.
About HCW Biologics:
HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/
Company Contact:
Rebecca Byam
CFO
HCW Biologics Inc.
rebeccabyam@hcwbiologics.com
FAQ
What Nasdaq compliance requirements did HCW Biologics (HCWB) regain in June 2025?
When did HCWB meet other Nasdaq listing requirements in 2025?
Is HCW Biologics (HCWB) now fully compliant with Nasdaq listing requirements?
What is HCW Biologics' main business focus?
